Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

ClinicalTrials.gov ID: NCT02616614

Public ClinicalTrials.gov record NCT02616614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel to Onexton® Gel in Subjects With Acne Vulgaris

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris

Study identification

NCT ID
NCT02616614
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Actavis Inc.
Industry
Enrollment
862 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years to 40 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2015
Primary completion
Sep 30, 2015
Completion
Oct 31, 2015
Last update posted
May 26, 2020

2015

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Alliance Dermatology Phoenix Arizona 85032
Estudy Chula Vista California 91911
Estudy La Mesa California 91942
Tampa Bay Medical Research Clearwater Florida 33761
AMB Research Center Miami Florida 33144
Meridian Clinical Research Savannah Georgia 31406
Heartland Research Assoc Augusta Kansas 67010
Heartland Research Assoc Wichita Kansas 67207
Sundance Clinical Research St Louis Missouri 63141
Meridian Clinical Research Norfolk Nebraska 68701
Meridian Clinical Research Omaha Nebraska 68134
Dermatology Consulting Services High Point North Carolina 27262
Sterling Research Group Cincinnati Ohio 45246
Discover Research Beaumont Texas 77701
DiscoverResearch Inc Bryan Texas 77802
Reseacr Across America Dallas Texas 75234
Clinical Research Assoc. of Tidewater Norfolk Virginia 23507

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02616614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 26, 2020 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02616614 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →